| Nov 21 |
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer
|
| Nov 20 |
Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
|
| Nov 19 |
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC
|
| Nov 19 |
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year
|
| Nov 18 |
CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC
|
| Nov 14 |
RNA Stock Hits Record High on Entering the Cardiac Disease Space
|
| Nov 12 |
Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View
|
| Nov 12 |
Castle Biosciences' (NASDAQ:CSTL) Performance Is Even Better Than Its Earnings Suggest
|
| Nov 8 |
Castle Biosciences (CSTL) Is a Great Choice for 'Trend' Investors, Here's Why
|
| Nov 8 |
Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting
|
